NASDAQ:ACHV Achieve Life Sciences (ACHV) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free ACHV Stock Alerts $4.54 +0.03 (+0.66%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.38▼$4.6850-Day Range$3.82▼$5.1452-Week Range$3.03▼$10.30Volume124,702 shsAverage Volume180,570 shsMarket Capitalization$96.22 millionP/E RatioN/ADividend YieldN/APrice Target$16.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Achieve Life Sciences alerts: Email Address Achieve Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside259.4% Upside$16.33 Price TargetShort InterestBearish3.32% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.17Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.57) to ($1.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.38 out of 5 starsMedical Sector773rd out of 938 stocksDiagnostic Substances Industry11th out of 13 stocks 3.5 Analyst's Opinion Consensus RatingAchieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, Achieve Life Sciences has a forecasted upside of 259.4% from its current price of $4.55.Amount of Analyst CoverageAchieve Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.32% of the outstanding shares of Achieve Life Sciences have been sold short.Short Interest Ratio / Days to CoverAchieve Life Sciences has a short interest ratio ("days to cover") of 7.6.Change versus previous monthShort interest in Achieve Life Sciences has recently increased by 9.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAchieve Life Sciences does not currently pay a dividend.Dividend GrowthAchieve Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACHV. Previous Next 2.3 News and Social Media Coverage News SentimentAchieve Life Sciences has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Achieve Life Sciences this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Achieve Life Sciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Achieve Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 33.52% of the stock of Achieve Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Achieve Life Sciences are expected to grow in the coming year, from ($1.57) to ($1.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achieve Life Sciences is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achieve Life Sciences is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchieve Life Sciences has a P/B Ratio of 9.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatYour $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionStart Your Risk-Free Trial Here About Achieve Life Sciences Stock (NASDAQ:ACHV)Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc. is based in Vancouver, Canada.Read More ACHV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACHV Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comAchieve Life Sciences (NASDAQ:ACHV) Share Price Crosses Above Two Hundred Day Moving Average of $4.41March 28, 2024 | benzinga.comRecap: Achieve Life Sciences Q4 EarningsMarch 29, 2024 | Crypto Swap Profits (Ad)Grab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.March 28, 2024 | finance.yahoo.comAchieve Life Sciences Inc Reports Year-End Loss, Progresses Towards FDA ApprovalMarch 28, 2024 | globenewswire.comAchieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate UpdateMarch 28, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 28, 2024March 27, 2024 | msn.comAchieve Life Sciences Q4 2023 Earnings PreviewMarch 21, 2024 | americanbankingnews.comAchieve Life Sciences (NASDAQ:ACHV) Shares Cross Above 200-Day Moving Average of $4.42March 29, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 21, 2024 | americanbankingnews.comAchieve Life Sciences (ACHV) Set to Announce Quarterly Earnings on ThursdayMarch 20, 2024 | finance.yahoo.comAchieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual MeetingMarch 18, 2024 | bizjournals.comOver $1 million raised for community initiatives, scholarships at Donald Driver's Driven To Achieve Awards: SlideshowMarch 16, 2024 | ca.finance.yahoo.comACHV Apr 2024 2.500 callMarch 14, 2024 | finance.yahoo.comAchieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024March 11, 2024 | msn.comHow AI Is Saving LivesMarch 11, 2024 | nj.comWATCH: No. 12 College Achieve Asbury Park celebrates winning the Group 1 state titleMarch 11, 2024 | msn.comLuka Doncic Creates NBA History; Becomes the First Player to Achieve THIS FeatMarch 10, 2024 | msn.comNo. 12 College Achieve Asbury Park owns Group 1, easily wins title in 1st yearMarch 8, 2024 | finance.yahoo.comLife Science Virtual Investor Forum Presentations Now Available for Online ViewingMarch 6, 2024 | globenewswire.comAchieve Life Sciences Announces Participation at Upcoming Investor ConferencesMarch 1, 2024 | finance.yahoo.comACHV: ORCA-OL to Start 2Q:24February 29, 2024 | markets.businessinsider.comBuy Rating for Achieve Life Sciences on Cytisinicline’s Promising Future and Solid FinancialsFebruary 29, 2024 | msn.comAchieve Life Sciences stock falls 11% amid FDA update, securities saleFebruary 29, 2024 | markets.businessinsider.comAchieve Reveals Agreement With FDA On Long-term Cytisinicline Exposure Data For Safety RisksFebruary 29, 2024 | globenewswire.comAchieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA SubmissionFebruary 29, 2024 | globenewswire.comAchieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private PlacementFebruary 21, 2024 | usnews.comDanish Farmers Must Cut Production to Achieve Climate Goal, Says Government AdvisorSee More Headlines Receive ACHV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/16/2023Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:ACHV CUSIP68230A10 CIK949858 Webachievelifesciences.com Phone(604) 210-2217Fax425-686-1600Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$16.33 High Stock Price Target$20.00 Low Stock Price Target$11.00 Potential Upside/Downside+259.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-632.85% Return on Assets-136.78% Debt Debt-to-Equity Ratio4.02 Current Ratio5.36 Quick Ratio5.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book9.88Miscellaneous Outstanding Shares21,170,000Free Float20,743,000Market Cap$96.22 million OptionableOptionable Beta1.32 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Richard A. B. Stewart (Age 65)Executive Chairman Comp: $575kMr. John A. Bencich M.B.A. (Age 47)CEO & Director Comp: $733.12kDr. Cindy Jacobs M.D. (Age 66)Ph.D., President, Chief Medical Officer & Director Comp: $614.25kMr. Jerry Wan (Age 42)Principal Accounting Officer Dr. Anthony Clarke (Age 68)Chief Scientific Officer Comp: $546kMs. Jaime XinosExecutive Vice President of CommercialMore ExecutivesKey CompetitorsAlpha TeknovaNASDAQ:TKNOVolitionRxNYSE:VNRXImmuCellNASDAQ:ICCCAspira Women's HealthNASDAQ:AWHCardio DiagnosticsNASDAQ:CDIOView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 11,757 shares on 3/11/2024Ownership: 2.861%Vanguard Group Inc.Bought 11,757 shares on 2/15/2024Ownership: 2.862%Citadel Advisors LLCSold 21,700 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 23,027 shares on 2/13/2024Ownership: 0.482%Simplex Trading LLCSold 3,800 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ACHV Stock Analysis - Frequently Asked Questions Should I buy or sell Achieve Life Sciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHV shares. View ACHV analyst ratings or view top-rated stocks. What is Achieve Life Sciences' stock price target for 2024? 3 brokers have issued 12-month price objectives for Achieve Life Sciences' shares. Their ACHV share price targets range from $11.00 to $20.00. On average, they predict the company's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 259.4% from the stock's current price. View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts. How have ACHV shares performed in 2024? Achieve Life Sciences' stock was trading at $4.12 at the beginning of 2024. Since then, ACHV stock has increased by 10.3% and is now trading at $4.5450. View the best growth stocks for 2024 here. Are investors shorting Achieve Life Sciences? Achieve Life Sciences saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 701,800 shares, an increase of 9.1% from the February 29th total of 643,200 shares. Based on an average daily volume of 92,000 shares, the short-interest ratio is currently 7.6 days. View Achieve Life Sciences' Short Interest. How were Achieve Life Sciences' earnings last quarter? Achieve Life Sciences, Inc. (NASDAQ:ACHV) issued its earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.07. During the same quarter last year, the business earned ($0.76) EPS. When did Achieve Life Sciences' stock split? Shares of Achieve Life Sciences reverse split on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Achieve Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI). Who are Achieve Life Sciences' major shareholders? Achieve Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.86%), Vanguard Group Inc. (2.86%), Raymond James & Associates (0.73%), Northern Trust Corp (0.48%), Madison Park Capital Advisors LLC (0.05%) and Simplex Trading LLC (0.00%). View institutional ownership trends. How do I buy shares of Achieve Life Sciences? Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACHV) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.